Literature DB >> 2552499

Proton spectroscopic imaging (Dixon method) of the liver: clinical utility.

L D Schertz1, J K Lee, J P Heiken, P L Molina, W G Totty.   

Abstract

The contribution of proton spectroscopic (PS) imaging to magnetic resonance (MR) imaging of the liver was assessed at 0.5 T in 55 patients with known or suspected hepatic malignancy. PS images were compared subjectively with T1- and T2-weighted spin-echo (SE) images for hepatic lesion detection and conspicuity. For hepatic metastases (n = 27), PS images were equal to T1-weighted images in lesion detection in 17 patients but showed fewer lesions in five patients and false-negative results in two. When compared with T2-weighted images, PS images depicted more lesions in six patients, an equal number of lesions in 18, and fewer lesions in two. Hepatomas (n = 8) were detected with each sequence in all patients. Hepatomas were often more conspicuous on PS images than on T2-weighted images; they were of equal conspicuity on PS and T1-weighted images in most cases. Whereas fatty infiltration (n = 16) appeared on PS images as areas of low signal intensity similar to that of paraspinal muscle, it produced no detectable abnormality on either T1- or T2-weighted images. PS imaging is inferior to T1-weighted SE imaging in the detection of hepatic metastases. The major role of PS imaging at intermediate field strength is to differentiate focal fatty infiltration from hepatic metastases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552499     DOI: 10.1148/radiology.173.2.2552499

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Hepatic fat assessment using advanced Magnetic Resonance Imaging.

Authors:  Yong Pang; Baiying Yu; Xiaoliang Zhang
Journal:  Quant Imaging Med Surg       Date:  2012-09

2.  Preoperative evaluation of patients for liver resection. Appropriate CT imaging.

Authors:  R C Karl; S S Morse; R D Halpert; R A Clark
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.